KRAS and non-small cell lung carcinoma: With the prospect of targeted treatment of patients with KRAS G12C mutated NSCLC, we retrospectively aimed to explore the frequency of KRAS mutations, clinical characteristics and the prognostic effects of KRAS in a cohort of patients diagnosed with non-squamous NSCLC disease stage I–IV in three university hospitals in Norway.